Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2018

Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group

Emmanuel Meyer
  • Fonction : Auteur
Christine Théodore
  • Fonction : Auteur
  • PersonId : 907559
Christophe Hennequin
  • Fonction : Auteur
  • PersonId : 835751
Christian Carrie
  • Fonction : Auteur
  • PersonId : 898495

Résumé

Background Renal cell carcinoma (RCC) is usually considered radioresistant, but stereotactic radiation therapy (SRT) may increase local disease control. This study aimed to assess the benefit of SRT in the management of metastatic RCC patients. Methods Data of all RCC patients who received SRT between 2008 and 2015 with curative intent were retrospectively collected in six French referral centres. Local control (LC), progression-free survival (PFS), local recurrence-free survival (LRFS), time to systemic therapy (TTS) and overall survival (OS) were assessed. Results One hundred and eighty-eight patients treated with SRT for 252 RCC metastases (brain [n = 120]; spine [n = 75]; and others [n = 57]) were recensed. SRT was performed for oligoprogressive disease (101 patients), oligometastatic disease (80 patients) or residual tumour after a partial response to systemic treatment (7 patients). The median biologically effective dose was 78 Gy. For the whole population, local control rates at 6, 12 and 24 months were 87.5%, 82.9% and 77.6%, respectively; median PFS, LRFS, TTS and OS were 8.5, 23.2, 13.2 and 29.2 months, respectively. Among patients treated for oligoprogressive/oligometastatic disease, the median PFS, TTS, and OS were 8.6/7.6, 10.5/14.2 and 23.2/33.9 months, respectively. Among the 7 patients treated with SRT after partial response to systemic treatment, no relapse occurred for 3 of them after a median follow-up of 22 months. Acute and late severe toxicities were noted in 5 (2.6%) patients. Conclusions SRT is effective and safe for oligometastatic and oligoprogressive RCC patients and may delay introduction or change of systemic therapy.
Fichier non déposé

Dates et versions

hal-02021697 , version 1 (16-02-2019)

Identifiants

Citer

Emmanuel Meyer, David Pasquier, Guillemette Bernadou, Gilles Calais, Pierre Maroun, et al.. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group. European Journal of Cancer, 2018, 98, pp.38-47. ⟨10.1016/j.ejca.2018.04.008⟩. ⟨hal-02021697⟩
131 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More